|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | CSD00331 |
| 保存条件 | store at -80℃ |
| 用途 | 仅用于科研用途 |
| 应用范围 | |
| 抗原来源 | CHO cells |
| CAS编号 | 1401812-88-1 |
| 保质期 | 一年 |
| 抗体名 | Lifastuzumab Vedotin ( 维汀-利法妥珠单抗 ) |
| 是否单克隆 | |
| 克隆性 | |
| 靶点 | SLC34A2[Homo sapiens] |
| 适应物种 | |
| 形态 | |
| 宿主 | |
| 标记物 | |
| 包装规格 | 100μg |
| 纯度 | % |
| 亚型 | |
| 标识物 | |
| 浓度 | 95% |
| 免疫原 | |
| 是否进口 | 否 |
Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
货号（Catalog No.）
CSD00331
通用名INN
Lifastuzumab Vedotin
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
别名(Alternative names)
DNIB0600A (conjugate),MNIB2126A (non conjugate)
靶点;物种(Specificity target name;species)
SLC34A2[Homo sapiens]
种类(Species)
Humanized
受体鉴定(Receptor identification)
IgG1-kappa
化学信息
CAS
1401812-88-1
存储条件(Storage)
store at -80°C
